TickerStat.comEloxx Pharmaceuticals annual depreciation and amortization
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Depreciation & Amortization Growth & History (ELOX)
Eloxx Pharmaceuticals's depreciation and amortization was $0 for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$35,000 | — |
| 2024 | 2024-12-31 | $35,000 | −$78,000 | −69.03% |
| 2023 | 2023-12-31 | $113,000 | $36,000 | +46.75% |
| 2022 | 2022-12-31 | $77,000 | −$37,000 | −32.46% |
| 2021 | 2021-12-31 | $114,000 | $46,000 | +67.65% |
| 2020 | 2020-12-31 | $68,000 | −$19,000 | −21.84% |
| 2019 | 2019-12-31 | $87,000 | −$129,000 | −59.72% |
| 2018 | 2018-12-31 | $216,000 | $177,000 | +453.85% |
| 2017 · Dec 31 | 2017-12-31 | $39,000 | $31,000 | +387.50% |
| 2017 · Jun 30 | 2017-06-30 | $44,075 | −$49,319 | −52.81% |
| 2016 · Dec 31 | 2016-12-31 | $8,000 | $3,000 | +60.00% |
| 2016 · Jun 30 | 2016-06-30 | $93,394 | −$83,680 | −47.26% |
| 2015 · Dec 31 | 2015-12-31 | $5,000 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $177,074 | −$172,582 | −49.36% |
| 2014 | 2014-06-30 | $349,656 | $56,027 | +19.08% |
| 2013 | 2013-06-30 | $293,629 | $35,606 | +13.80% |
| 2012 | 2012-06-30 | $258,023 | $114,749 | +80.09% |
| 2011 | 2011-06-30 | $143,274 | $16,707 | +13.20% |
| 2010 | 2010-06-30 | $126,567 | — | — |
Eloxx Pharmaceuticals quarterly depreciation and amortization
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q4.15
Q1.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | $13,000 | −$10,000 | −43.48% |
| Q2 2023 | 2023-06-30 | $12,000 | −$10,000 | −45.45% |
| Q1 2023 | 2023-03-31 | $15,000 | −$6,000 | −28.57% |
| Q3 2022 | 2022-09-30 | $23,000 | −$7,000 | −23.33% |
| Q2 2022 | 2022-06-30 | $22,000 | −$18,000 | −45.00% |
| Q1 2022 | 2022-03-31 | $21,000 | $5,000 | +31.25% |
| Q3 2021 | 2021-09-30 | $30,000 | $14,000 | +87.50% |
| Q2 2021 | 2021-06-30 | $40,000 | $23,000 | +135.29% |
| Q1 2021 | 2021-03-31 | $16,000 | −$3,000 | −15.79% |
| Q3 2020 | 2020-09-30 | $16,000 | −$2,000 | −11.11% |
| Q2 2020 | 2020-06-30 | $17,000 | $0 | 0.00% |
| Q1 2020 | 2020-03-31 | $19,000 | −$14,000 | −42.42% |
| Q3 2019 | 2019-09-30 | $18,000 | −$57,000 | −76.00% |
| Q2 2019 | 2019-06-30 | $17,000 | −$8,000 | −32.00% |
| Q1 2019 | 2019-03-31 | $33,000 | $12,000 | +57.14% |
| Q3 2018 | 2018-09-30 | $75,000 | $66,792 | +813.74% |
| Q2 2018 | 2018-06-30 | $25,000 | $18,000 | +257.14% |
| Q1 2018 · Mar 31 | 2018-03-31 | $21,000 | $11,601 | +123.43% |
| Q1 2018 · Sep 30 | 2017-09-30 | $8,208 | −$3,427 | −29.45% |
| Q4 2017 · Jun 30 | 2017-06-30 | $7,000 | — | — |
| Q1 2017 · Mar 31 | 2017-03-31 | $9,399 | −$9,540 | −50.37% |
| Q4 2016 | 2016-12-31 | $13,874 | −$15,682 | −53.06% |
| Q1 2017 · Sep 30 | 2016-09-30 | $11,635 | −$20,458 | −63.75% |
| Q1 2016 · Mar 31 | 2016-03-31 | $18,939 | −$19,797 | −51.11% |
| Q4 2015 | 2015-12-31 | $29,556 | −$10,518 | −26.25% |
| Q1 2016 · Sep 30 | 2015-09-30 | $32,093 | −$28,053 | −46.64% |
| Q3 2015 | 2015-03-31 | $38,736 | −$46,945 | −54.79% |
| Q2 2015 | 2014-12-31 | $40,074 | −$38,356 | −48.90% |
| Q1 2015 | 2014-09-30 | $60,146 | −$14,647 | −19.58% |
| Q3 2014 | 2014-03-31 | $85,681 | $14,190 | +19.85% |
| Q2 2014 | 2013-12-31 | $78,430 | $11,582 | +17.33% |
| Q1 2014 | 2013-09-30 | $74,793 | $11,221 | +17.65% |
| Q3 2013 | 2013-03-31 | $71,491 | $4,978 | +7.48% |
| Q2 2013 | 2012-12-31 | $66,848 | $5,181 | +8.40% |
| Q1 2013 | 2012-09-30 | $63,572 | $6,253 | +10.91% |
| Q3 2012 | 2012-03-31 | $66,513 | $30,270 | +83.52% |
| Q2 2012 | 2011-12-31 | $61,667 | $26,655 | +76.13% |
| Q1 2012 | 2011-09-30 | $57,319 | $23,027 | +67.15% |
| Q3 2011 | 2011-03-31 | $36,243 | — | — |
| Q2 2011 | 2010-12-31 | $35,012 | — | — |
| Q1 2011 | 2010-09-30 | $34,292 | — | — |
Eloxx Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Eloxx Pharmaceuticals's depreciation and amortization decreased from $68,000 to $0, a change of −$68,000. The latest reported quarter, Q3 2023, shows $13,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...